AstraZeneca mines for positives in Imfinzi’s failed Mystic lung cancer trial
AstraZeneca mines for positives in Imfinzi’s failed Mystic lung cancer trial
Can Bristol-Myers’ latest Opdivo results preserve its small-cell lung cancer nod?
Can Bristol-Myers’ latest Opdivo results preserve its small-cell lung cancer nod?
Roche wins key cancer drug approval, but taking on Merck remains a challenge
Roche wins key cancer drug approval, but taking on Merck remains a challenge
Roche’s Tecentriq gets first-line lung cancer approval
Roche’s Tecentriq gets first-line lung cancer approval
Roche’s Tecentriq wins key lung cancer approval. Its prize? A showdown with formidable Merck
Roche’s Tecentriq wins key lung cancer approval. Its prize? A showdown with formidable Merck
One more shot at slowing Keytruda’s first-line lung cancer domination
One more shot at slowing Keytruda’s first-line lung cancer domination
BMS’ second small-cell trial flop endangers Opdivo lung cancer approval: analyst
BMS’ second small-cell trial flop endangers Opdivo lung cancer approval: analyst
Roche yanks Tecentriq kidney cancer applications as Merck, Pfizer speed toward approvals
Roche yanks Tecentriq kidney cancer applications as Merck, Pfizer speed toward approvals
Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years
Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years
Deep Dive: Immunovative Therapies’ Next-Generation Cancer Vaccine Could Change the Game
Deep Dive: Immunovative Therapies’ Next-Generation Cancer Vaccine Could Change the Game
The most disputed sales outlooks in biopharma
The most disputed sales outlooks in biopharma
Ready to Roll! Ten Q3 Biotech Earnings Reports to Watch Next Week
Ready to Roll! Ten Q3 Biotech Earnings Reports to Watch Next Week
Keytruda growth fuels Merck investment
Keytruda growth fuels Merck investment
ESMO: Roche’s latest Tecentriq lung results underscore Avastin’s talents, executive says
On Monday at the European Society for Medical Oncology 2018 Congress, new data showed that Roche’s Tecentriq, in tandem with chemo, could improve survival for newly diagnosed lung cancer patients. … Continue Reading ESMO: Roche’s latest Tecentriq lung results underscore Avastin’s talents, executive says
Science behind Nobel winners spawned one of the biggest marketing duels in pharma history
Science behind Nobel winners spawned one of the biggest marketing duels in pharma history
A timeline of key moments in the development of checkpoint inhibitors
A timeline of key moments in the development of checkpoint inhibitors
